SummitTX Capital’s CRISPR Therapeutics CRSP Stock Holding History

SummitTX Capital’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,448	Closed	-$212K	–	827
2026 Q1	$212K	Buy	+4,448	New	+$235K	0.01%	691

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SummitTX Capital's CRSP Position: Q2 2026 in Review

SummitTX Capital sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 4,448 shares — an estimated $212K sold.

SummitTX Capital first reported a position in CRSP in Q1 2026 and held it in 1 quarter. The position peaked at $212K in Q1 2026. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

SummitTX Capital reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
SummitTX Capital sold 4,448 CRISPR Therapeutics shares in Q2 2026, an estimated $212K.
SummitTX Capital first reported a position in CRISPR Therapeutics in Q1 2026 and held it in 1 quarter.
SummitTX Capital's CRISPR Therapeutics position peaked at $212K in Q1 2026.
521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.